Amneal Pharmaceuticals (NASDAQ:AMRX) Trading Down 7.1%

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s share price fell 7.1% during trading on Thursday . The stock traded as low as $5.59 and last traded at $5.62. 1,801,136 shares were traded during trading, an increase of 18% from the average session volume of 1,521,437 shares. The stock had previously closed at $6.05.

Wall Street Analyst Weigh In

Several brokerages have commented on AMRX. The Goldman Sachs Group upped their target price on shares of Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a “buy” rating in a research report on Monday, March 4th. Barclays upped their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, January 29th. Piper Sandler upped their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Finally, StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 4th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $7.31.

Amneal Pharmaceuticals Stock Performance

The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -18.19 and a beta of 1.33. The company has a current ratio of 1.63, a quick ratio of 0.94 and a debt-to-equity ratio of 121.31. The stock’s 50 day moving average is $5.72 and its two-hundred day moving average is $5.17.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, March 1st. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.07. Amneal Pharmaceuticals had a negative net margin of 3.51% and a positive return on equity of 126.04%. The company had revenue of $616.98 million during the quarter, compared to the consensus estimate of $630.67 million. Analysts expect that Amneal Pharmaceuticals, Inc. will post 0.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Amneal Pharmaceuticals by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 13,548,300 shares of the company’s stock valued at $57,174,000 after purchasing an additional 412,599 shares during the last quarter. Rubric Capital Management LP raised its holdings in Amneal Pharmaceuticals by 98.8% in the 4th quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company’s stock valued at $48,560,000 after acquiring an additional 3,975,500 shares during the period. LSV Asset Management raised its holdings in Amneal Pharmaceuticals by 10.5% in the 3rd quarter. LSV Asset Management now owns 1,429,300 shares of the company’s stock valued at $6,032,000 after acquiring an additional 136,100 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Amneal Pharmaceuticals by 2.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,329,508 shares of the company’s stock valued at $8,070,000 after acquiring an additional 26,875 shares during the period. Finally, Teacher Retirement System of Texas raised its holdings in Amneal Pharmaceuticals by 3.4% in the 4th quarter. Teacher Retirement System of Texas now owns 744,752 shares of the company’s stock valued at $4,521,000 after acquiring an additional 24,651 shares during the period. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.